Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

Brian W. Loggie, Ronald A. Fleming, Kim R. Geisinger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: A phase I/II clinical trial of surgical cytoreduction combined with intraperitoneal hyperthermic chemotherapy (IPHC) for patients with disseminated peritoneal carcinoma was begun in December 1991. The use of peritoneal cytology to assess this treatment modality was the objective of this study. STUDY DESIGN: Adult patients with primary intraabdominal cancer with peritoneal dissemination underwent surgical debulking and intraoperative, two-hour, heated abdominopelvic perfusion with mitomycin C (MMC). Peritoneal washings were sent before and after IPHC, and the use of peritoneal cytology in this setting was reviewed retrospectively. RESULTS: Twenty patients (9 female, 11 male) with adenocarcinoma (19) and one with epithelial mesothelioma, all with balky peritoneal disease, were treated. Pre- and post-IPHC cytologic specimens were available for 18 cases. Cytology was tumor negative in three cases before and after IPHC. Conversion to negative post-IPHC cytology was seen in 6 of 15 cases and correlated with total or near-total tumor debulking (Fisher's exact test, P = .002). For 13 patients with follow-up ≤6 months, 6 patients with both negative post-IPHC cytology and tumor ≤ 1 g were alive at 6 months; of 7 patients with residual gross tumor or positive post-IPHC cytology, 5 had died within 6 months (P = .02). CONCLUSION: Some patients undergoing IPHC with tumor-positive peritoneal cytology will convert to negative cytology following IPHC. This correlates with total or near-total tumor debulking and is associated with improved survival.

Original languageEnglish
Pages (from-to)1154-1158
Number of pages5
JournalActa Cytologica
Volume40
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Cell Biology
Carcinoma
Drug Therapy
Neoplasms
Peritoneal Diseases
Phase II Clinical Trials
Clinical Trials, Phase I
Mesothelioma
Residual Neoplasm
Mitomycin
Adenocarcinoma
Perfusion
Survival

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Cell Biology
  • Histology

Cite this

Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. / Loggie, Brian W.; Fleming, Ronald A.; Geisinger, Kim R.

In: Acta Cytologica, Vol. 40, No. 6, 1996, p. 1154-1158.

Research output: Contribution to journalArticle

@article{ac60e244be7a414cb76748f6c7e9c0c5,
title = "Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis",
abstract = "OBJECTIVE: A phase I/II clinical trial of surgical cytoreduction combined with intraperitoneal hyperthermic chemotherapy (IPHC) for patients with disseminated peritoneal carcinoma was begun in December 1991. The use of peritoneal cytology to assess this treatment modality was the objective of this study. STUDY DESIGN: Adult patients with primary intraabdominal cancer with peritoneal dissemination underwent surgical debulking and intraoperative, two-hour, heated abdominopelvic perfusion with mitomycin C (MMC). Peritoneal washings were sent before and after IPHC, and the use of peritoneal cytology in this setting was reviewed retrospectively. RESULTS: Twenty patients (9 female, 11 male) with adenocarcinoma (19) and one with epithelial mesothelioma, all with balky peritoneal disease, were treated. Pre- and post-IPHC cytologic specimens were available for 18 cases. Cytology was tumor negative in three cases before and after IPHC. Conversion to negative post-IPHC cytology was seen in 6 of 15 cases and correlated with total or near-total tumor debulking (Fisher's exact test, P = .002). For 13 patients with follow-up ≤6 months, 6 patients with both negative post-IPHC cytology and tumor ≤ 1 g were alive at 6 months; of 7 patients with residual gross tumor or positive post-IPHC cytology, 5 had died within 6 months (P = .02). CONCLUSION: Some patients undergoing IPHC with tumor-positive peritoneal cytology will convert to negative cytology following IPHC. This correlates with total or near-total tumor debulking and is associated with improved survival.",
author = "Loggie, {Brian W.} and Fleming, {Ronald A.} and Geisinger, {Kim R.}",
year = "1996",
language = "English",
volume = "40",
pages = "1154--1158",
journal = "Acta Cytologica",
issn = "0001-5547",
publisher = "Science Printers and Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

AU - Loggie, Brian W.

AU - Fleming, Ronald A.

AU - Geisinger, Kim R.

PY - 1996

Y1 - 1996

N2 - OBJECTIVE: A phase I/II clinical trial of surgical cytoreduction combined with intraperitoneal hyperthermic chemotherapy (IPHC) for patients with disseminated peritoneal carcinoma was begun in December 1991. The use of peritoneal cytology to assess this treatment modality was the objective of this study. STUDY DESIGN: Adult patients with primary intraabdominal cancer with peritoneal dissemination underwent surgical debulking and intraoperative, two-hour, heated abdominopelvic perfusion with mitomycin C (MMC). Peritoneal washings were sent before and after IPHC, and the use of peritoneal cytology in this setting was reviewed retrospectively. RESULTS: Twenty patients (9 female, 11 male) with adenocarcinoma (19) and one with epithelial mesothelioma, all with balky peritoneal disease, were treated. Pre- and post-IPHC cytologic specimens were available for 18 cases. Cytology was tumor negative in three cases before and after IPHC. Conversion to negative post-IPHC cytology was seen in 6 of 15 cases and correlated with total or near-total tumor debulking (Fisher's exact test, P = .002). For 13 patients with follow-up ≤6 months, 6 patients with both negative post-IPHC cytology and tumor ≤ 1 g were alive at 6 months; of 7 patients with residual gross tumor or positive post-IPHC cytology, 5 had died within 6 months (P = .02). CONCLUSION: Some patients undergoing IPHC with tumor-positive peritoneal cytology will convert to negative cytology following IPHC. This correlates with total or near-total tumor debulking and is associated with improved survival.

AB - OBJECTIVE: A phase I/II clinical trial of surgical cytoreduction combined with intraperitoneal hyperthermic chemotherapy (IPHC) for patients with disseminated peritoneal carcinoma was begun in December 1991. The use of peritoneal cytology to assess this treatment modality was the objective of this study. STUDY DESIGN: Adult patients with primary intraabdominal cancer with peritoneal dissemination underwent surgical debulking and intraoperative, two-hour, heated abdominopelvic perfusion with mitomycin C (MMC). Peritoneal washings were sent before and after IPHC, and the use of peritoneal cytology in this setting was reviewed retrospectively. RESULTS: Twenty patients (9 female, 11 male) with adenocarcinoma (19) and one with epithelial mesothelioma, all with balky peritoneal disease, were treated. Pre- and post-IPHC cytologic specimens were available for 18 cases. Cytology was tumor negative in three cases before and after IPHC. Conversion to negative post-IPHC cytology was seen in 6 of 15 cases and correlated with total or near-total tumor debulking (Fisher's exact test, P = .002). For 13 patients with follow-up ≤6 months, 6 patients with both negative post-IPHC cytology and tumor ≤ 1 g were alive at 6 months; of 7 patients with residual gross tumor or positive post-IPHC cytology, 5 had died within 6 months (P = .02). CONCLUSION: Some patients undergoing IPHC with tumor-positive peritoneal cytology will convert to negative cytology following IPHC. This correlates with total or near-total tumor debulking and is associated with improved survival.

UR - http://www.scopus.com/inward/record.url?scp=0030445974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030445974&partnerID=8YFLogxK

M3 - Article

C2 - 8960022

AN - SCOPUS:0030445974

VL - 40

SP - 1154

EP - 1158

JO - Acta Cytologica

JF - Acta Cytologica

SN - 0001-5547

IS - 6

ER -